Cresco Labs Lowers Q4 2021 Revenue Guidance After Reducing Third Party Agreements

Cresco Labs (CSE: CL) announced on Thursday that it is exiting exclusive distributorship agreements of certain third-party branded products in California. This results in the cannabis operator lowering its revenue guidance for Q4 2021 to be between $235 million and $245 million.

“As we continue to implement localization strategies tailored to each state’s market dynamics, this decision will enable us to put our full weight behind our rapidly growing owned-brand portfolio in California, while also expanding profitability margins for our overall business,” said Cresco Labs CEO Charlie Bachtell.

Aside from shifting towards owned-brand distribution, increasing profitability is also one of the strategies that led to the company’s decision.

However, the firm reiterated that its Q4 2021 guidance for adjusted EBITDA and gross margins still remain at 30% and over 50%, respectively. It will also continue partnering with a small group of brands in the US state.

Cresco Labs last traded at $11.99 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Cresco Labs Insiders Unload $32.8 Million Worth Of Shares In Early Morning Trade

Yesterday morning, popular cannabis investor Todd Harrison commented on Twitter that unusual trading activity had...

Tuesday, December 8, 2020, 07:17:38 AM

Cresco Labs To Pay US$2.0 Billion In Stock To Acquire Columbia Care

Consolidation within the US cannabis space continued this morning with the proposed combination of Columbia...

Wednesday, March 23, 2022, 07:58:57 AM

Cresco Labs: Canaccord Cuts Price Target On Muted Growth, Pricing Challenges

On August 17, Cresco Labs (CSE: CL) reported its second quarter financial results. The company...

Friday, August 19, 2022, 02:12:00 PM

Cresco Labs: Analysts Raise Targets Following Blowout Quarter

On November 18th, Cresco Labs (CSE: CL) reported their third quarter financial results. The company...

Friday, November 20, 2020, 12:09:00 PM

Haywood Initiates Coverage On Cresco Labs With $14.00 Price Target

Last week, Haywood Securities initiated coverage on Cresco Labs (CSE: CL) with a C$14.00 price...

Wednesday, November 4, 2020, 01:59:00 PM